Lactobacillus casei YWC-01 preparation for degrading uric acid and application thereof
Through enzyme catalysis of the YWC-01 strain of C. cerevisiae, the efficient degradation of uric acid is achieved, and the problems of poor degradation effect and side effects in the prior art are solved, and a safe and effective uric acid control method is provided.
Patent Information
- Application Number
- CN202411461982.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-10-18
AI Technical Summary
The prior art has no significant effect in degrading uric acid and has side effects, making it difficult to effectively control hyperuricemia.
A strain of C. cerevisiae YWC-01 is provided, which can produce enzymes that catalyze the degradation of uric acid, which can degrade all uric acid at an initial concentration of 1 g/L within 48 hours, and its preparation can be used to prepare liquid or solid powder form. Uric acid-lowering agent.
The efficient biodegradation of uric acid is achieved, providing a safe and effective method to control blood uric acid levels, with important application prospects in the treatment of hyperuricemia and related complications.
Smart Images

Figure CN119040210A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a Lactobacillus casei YWC-01 preparation for degrading uric acid and a preparation method and application thereof. Background Art
[0002] Hyperuricemia (HUA) refers to fasting blood uric acid levels exceeding the normal range twice on different days under a normal purine diet, that is, the blood uric acid level of adult males is greater than 420μmol / L and that of females is greater than 360μmol / L. According to the saturated solubility of uric acid in the blood, when the above concentration is exceeded, uric acid is prone to form crystals and deposit in tissues to form tophi, causing severe pain. At present, the number of HUA patients in my country has increased dramatically, posing a serious threat to people's health.
[0003] In the human body, intermediate products in the purine metabolic pathway, such as inosine and guanosine, can be further metabolized and converted into uric acid as the final product. Under normal circumstances, about two-thirds of uric acid is excreted through the kidneys, most of which is reabsorbed in the proximal tubules after glomerular filtration, and then excreted in the urine through the process of secretion and reabsorption. Another one-third of uric acid is converted into allantoin in the intestine through the decomposition of intestinal bacteria and then excreted from the body with feces. Because humans lack urate oxidase, they cannot degrade uric acid into more soluble allantoin, which hinders the excretion of uric acid, resulting in blood uric acid levels that are 3-10 times higher than non-primates, which is also one of the important reasons why humans are susceptible to HUA.
[0004] At present, the treatment or improvement of HUA is mainly divided into drug therapy and dietary intervention, among which drug therapy is the main method. Commonly used drugs include allopurinol, febuxostat, benzbromarone and urate oxidase (rasburicase), etc., which mainly reduce the production of uric acid by inhibiting the activity of xanthine oxidase or increase the excretion of uric acid by reducing the reabsorption of uric acid, so as to control the level of blood uric acid. The main mechanism of action of urate oxidase is to further degrade uric acid into more soluble allantoin, making it easier to be excreted from the kidneys. Although there are reports on the biodegradation of nucleosides such as inosine by Lactobacillus casei, there are no studies on the biodegradation of uric acid by Lactobacillus casei. Although chemical drugs can play a certain role in controlling the onset of HUA, the series of side effects such as allergic reactions, liver damage, and abnormal renal function cannot be ignored. Dietary intervention mainly relieves HUA by limiting the intake of high-purine foods such as beer and fructose. Although it can control the level of blood uric acid to a certain extent, the effect is not ideal. Therefore, studying safer and more efficient methods to remove uric acid to control HUA has become a key scientific research problem that needs to be urgently solved in the current biomedical field. Summary of the invention
[0005] One of the purposes of the present invention is to provide a Lactobacillus casei YWC-01 strain for degrading uric acid in view of the problem that the drugs or foods for degrading and removing uric acid in the prior art are not effective and have side effects. The bacterial cells of the strain and the enzymes produced by the strain are safe for the human body, and both can efficiently biodegrade uric acid, and have important application prospects.
[0006] The second object of the present invention is to provide a Lactobacillus casei YWC-01 preparation for degrading uric acid and its application. The Lactobacillus casei YWC-01 preparation is made from the above-mentioned Lactobacillus casei YWC-01 strain for biodegrading uric acid and can efficiently biodegrade uric acid.
[0007] To this end, the first aspect of the present invention provides a Lactobacillus casei YWC-01 strain for degrading uric acid, which can produce an enzyme that catalyzes the degradation of uric acid and has a deposit number of CGMCC No.31534.
[0008] In some embodiments of the present invention, the Lactobacillus casei YWC-01 strain has an initial bacterial cell concentration of 8×10 8 / mL, the initial concentration of uric acid of 1g / L can be completely degraded and removed within 48 hours.
[0009] In other embodiments of the present invention, the crude enzyme produced by the Lactobacillus casei YWC-01 strain can completely remove uric acid with an initial concentration of 1 g / L within 18 hours at a protein concentration of 0.8 g / L.
[0010] The second aspect of the present invention provides a Lactobacillus casei YWC-01 preparation for degrading uric acid, which contains bacterial cells and / or crude enzymes of the Lactobacillus casei YWC-01 strain as described in the first aspect of the present invention; preferably, the Lactobacillus casei YWC-01 preparation contains the Lactobacillus casei YWC-01 strain as described in the first aspect of the present invention.
[0011] In some embodiments of the present invention, the uric acid-degrading Lactobacillus casei YWC-01 preparation is a liquid preparation; preferably, in the uric acid-degrading liquid preparation, the bacterial cell concentration of Lactobacillus casei YWC-01 strain is (1-10)×10 8 / mL; and / or, in the liquid preparation for degrading uric acid, the protein concentration of the crude enzyme of Lactobacillus casei YWC-01 strain is 0.1-1.0 g / L.
[0012] In other embodiments of the present invention, the uric acid-degrading Lactobacillus casei YWC-01 preparation is a solid powder preparation; preferably, in the uric acid-degrading solid powder preparation, the content of bacterial cells of Lactobacillus casei YWC-01 strain is (1-10)×10 8 / g, more preferably (8-10)×10 8 / g; and / or, in the solid powder preparation for degrading uric acid, the protein content of the crude enzyme of Lactobacillus casei YWC-01 strain is 0.1-1.0 g / kg, more preferably 8-10 g / kg.
[0013] The third aspect of the present invention provides a method for preparing the Lactobacillus casei YWC-01 preparation for degrading uric acid as described in the second aspect of the present invention, comprising:
[0014] Step B, inoculating the fermentation bacteria into a fermentation medium for fermentation culture to obtain a fermentation culture of Lactobacillus casei YWC-01 strain;
[0015] Step C, centrifuging the fermentation culture of Lactobacillus casei YWC-01 strain to harvest bacterial cells of Lactobacillus casei YWC-01 strain;
[0016] The fermentation bacteria are obtained by seed culture of the corresponding Lactobacillus casei YWC-01 strain.
[0017] According to the present invention, the fermentation medium comprises the following components in 1L of water:
[0018]
[0019] Preferably, the pH value of the fermentation medium is 7-8;
[0020] Further preferably, in step B, the fermentation culture temperature is 30-40°C, preferably 38-40°C.
[0021] According to some embodiments of the present invention, the preparation method further comprises:
[0022] Step K, subjecting the cell suspension of Lactobacillus casei YWC-01 strain to cell disruption treatment under low temperature conditions to obtain a cell-free disruption solution of Lactobacillus casei YWC-01 strain;
[0023] Step L, centrifuging the cell-free disrupted liquid of Lactobacillus casei YWC-01 strain, and taking the supernatant cell-free extract as the crude enzyme of Lactobacillus casei YWC-01 strain;
[0024] Wherein, the low temperature is 0-4°C.
[0025] The fourth aspect of the present invention provides a use of the uric acid-degrading Lactobacillus casei YWC-01 preparation according to the second aspect of the present invention or the uric acid-degrading Lactobacillus casei YWC-01 preparation prepared by the preparation method according to the third aspect of the present invention in the preparation of a uric acid-lowering agent, which comprises:
[0026] Step D, washing the bacterial cells of Lactobacillus casei YWC-01 strain with physiological saline to obtain a pure bacterial cell product of Lactobacillus casei YWC-01 strain;
[0027] Step E, in a physiological saline system, under low temperature conditions, using ultrasound to disrupt the pure bacterial cells of Lactobacillus casei YWC-01 strain, and taking the supernatant after centrifugation to obtain a cell-free extract as a crude enzyme pure product of Lactobacillus casei YWC-01 strain;
[0028] Step F, freeze-drying the pure bacterial cell product and / or the pure crude enzyme product of Lactobacillus casei YWC-01 strain, and diluting the freeze-dried Lactobacillus casei YWC-01 preparation to prepare a uric acid degrading agent;
[0029] Wherein, the low temperature is 0-4°C.
[0030] In some embodiments of the present invention, in step F, the freeze-dried Lactobacillus casei YWC-01 preparation is diluted with physiological saline to prepare a liquid uric acid-lowering agent.
[0031] In other embodiments of the present invention, in step F, the freeze-dried Lactobacillus casei YWC-01 preparation is diluted with edible starch to prepare a solid uric acid-lowering agent.
[0032] In some preferred embodiments of the present invention, the uric acid lowering agent is an oral preparation.
[0033] Studies have found that the Lactobacillus casei YWC-01 strain for biodegrading uric acid and the enzyme produced by the present invention are safe for the human body and can biodegrade uric acid, and have important application prospects in the efficient removal of uric acid for the treatment of human HUA and corresponding complications. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] In order to make the present invention easy to understand, the present invention is described below with reference to the accompanying drawings.
[0035] Figure 1 The molecular evolution tree of Lactobacillus casei YWC-01 based on 16S rDNA is shown.
[0036] Figure 2 This is the kinetic curve of biodegradation of uric acid by Lactobacillus casei YWC-01.
[0037] Figure 3 This is the kinetic curve of uric acid degradation catalyzed by Lactobacillus casei YWC-01.
[0038] Strain preservation
[0039] Lactobacillus casei was isolated and identified by Beijing Beike Yiran Biotechnology Co., Ltd. and has been deposited in the General Microbiological Center of the China Microbiological Culture Collection Committee (referred to as: CGMCC; address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing), deposit date: August 2, 2024, deposit number: CGMCC No. 31534. In the present invention, the strain is named Lactobacillus casei strain YWC-01, also known as Lactobacillus casei YWC-01. DETAILED DESCRIPTION
[0040] To make the present invention easy to understand, the present invention will be described in detail below. However, before describing the present invention in detail, it should be understood that the present invention is not limited to the specific embodiments described. It should also be understood that the terms used herein are only for describing specific embodiments and are not intended to be limiting.
[0041] Unless otherwise defined, all terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, preferred methods and materials are now described.
[0042] I. Terminology
[0043] The term "bacteria" as used in the present invention refers to living cells and / or dead cells of Lactobacillus casei.
[0044] The term "crude enzyme" used in the present invention refers to a cell-free extract obtained by breaking the bacterial cells of Lactobacillus casei and then centrifuging the supernatant.
[0045] The term "pure crude enzyme" used in the present invention refers to a cell-free extract obtained by breaking the pure bacterial cells of Lactobacillus casei and then centrifuging the supernatant.
[0046] The term "microbial preparation" used in the present invention refers to various forms of preparations that are made from microorganisms with medical research value, using traditional technology or modern biotechnology, and are used to prevent (health care), treat and diagnose various physiological symptoms of the human body.
[0047] The term "edible starch" as used in the present invention refers to starch that meets the "National Standard for Edible Starch" (GB 31637-2016 National Food Safety Standard Edible Starch).
[0048] The "water" used in the culture medium or fermentation culture process of the present invention, unless otherwise specified, refers to sterile pure water obtained by filtering through a 0.22μ filter membrane.
[0049] II. Implementation Plan
[0050] As mentioned above, the existing diet and drug therapy for controlling uric acid in the human body has slow and insignificant effects and has side effects. Therefore, the inventors have conducted a lot of in-depth research on the biodegradation of uric acid.
[0051] The inventors have noted that although lactic acid bacteria can promote intestinal health and reduce the accumulation of uric acid to some extent through a series of metabolic adjustments, there are no reports on the bacteria used to directly and efficiently biodegrade uric acid.
[0052] In recent years, the study of human microorganisms has been a hot topic and frontier in life science research. Although domestic and foreign scholars have screened out microbial strains from traditional foods that can inhibit uric acid synthesis and degrade uric acid precursors such as inosine and guanosine, no evidence has been found that Lactobacillus casei can directly and efficiently biodegrade uric acid.
[0053] The inventors also noted that Lactobacillus casei is a prokaryotic microorganism and is one of the probiotic species approved by the National Health Commission of my country for direct consumption by humans. It has the functions of promoting human intestinal health and improving human immune function and has been widely used in the fields of food, fermentation, beer and beverage production. However, no research reports on its biodegradation of uric acid have been found so far.
[0054] Based on long-term microbial research, the inventor successfully screened a strain of Lactobacillus casei from enzymes. The inventor found through research and exploration that the strain cells and the enzymes produced can completely degrade uric acid with an initial concentration of 1g / L within 48h and 18h, respectively, which not only has very important research value, but also has important application prospects in the efficient biodegradation and removal of uric acid. The present invention is thus obtained.
[0055] Therefore, the Lactobacillus casei YWC-01 strain for biodegrading uric acid according to the first aspect of the present invention can produce an enzyme that catalyzes the degradation of uric acid.
[0056] The inventor first successfully screened out a Lactobacillus casei YWC-01 strain from the enzyme. After extracting genomic DNA, it was determined to be Lactobacillus casei by PCR amplification and molecular identification based on 16S rDNA sequencing. Based on the above, the strain was identified and named as Lactobacillus casei YWC-01 strain (Lacticaseibacillus casei strain YWC01). The strain has been deposited in the General Microbiological Center of China Microbiological Culture Collection Administration, with a deposit number of CGMCC No.31534.
[0057] The inventors have found that during fermentation of Lactobacillus casei YWC-01 strain, yeast cells produced during the fermentation process contain more than one enzyme capable of catalyzing the degradation of uric acid. In the present invention, the mixture of these enzymes is referred to as crude enzyme, or Lactobacillus casei YWC-01 crude enzyme.
[0058] Further research found that the cell-free lysate after the Lactobacillus casei YWC-01 cells were lysed was centrifuged, and the supernatant cell-free extract was taken as the crude enzyme of Lactobacillus casei YWC-01. It is easy to understand that both the cells and the crude enzyme of Lactobacillus casei YWC-01 strain can catalyze the degradation of uric acid.
[0059] The results showed that the initial bacterial cell concentration of Lactobacillus casei YWC-01 was 8×10 8 / mL, the initial concentration of uric acid of 1g / L can be completely degraded and removed within 48 hours.
[0060] The crude enzyme produced by the Lactobacillus casei YWC-01 strain can completely degrade uric acid with an initial concentration of 1 g / L within 18 hours at a protein concentration of 0.8 g / L.
[0061] Based on the above, the second to fourth aspects of the present invention further provide the use or application of Lactobacillus casei for biodegrading uric acid as described in the first aspect of the present invention.
[0062] Specifically, the second aspect of the present invention provides a Lactobacillus casei YWC-01 preparation for biodegrading uric acid, which belongs to a microbial preparation for biodegrading uric acid, and contains bacterial cells and / or crude enzymes of the Lactobacillus casei YWC-01 strain as described in the first aspect of the present invention.
[0063] In some preferred embodiments of the present invention, the Lactobacillus casei YWC-01 preparation contains bacterial cells of the Lactobacillus casei YWC-01 strain as described in the first aspect of the present invention.
[0064] According to some embodiments of the present invention, the Lactobacillus casei YWC-01 preparation for biodegrading uric acid is a liquid preparation.
[0065] In some embodiments of the present invention, in the liquid preparation for biodegradation of uric acid, the bacterial cell concentration of the bacterial cells of the Lactobacillus casei YWC-01 strain is (1-10)×10 8 / mL.
[0066] In other embodiments of the present invention, in the liquid preparation for biodegradation of uric acid, the protein concentration of the crude enzyme of Lactobacillus casei YWC-01 strain is 0.1-1.0 g / L.
[0067] According to other embodiments of the present invention, the Lactobacillus casei YWC-01 preparation for biodegrading uric acid is a solid powder preparation.
[0068] In some embodiments of the present invention, in the solid powder preparation for biodegradation of uric acid, the bacterial cell content of Lactobacillus casei YWC-01 strain is (1-10)×108 / g, preferably (8-10)×10 8 / g.
[0069] In other embodiments of the present invention, in the solid powder preparation for biodegradation of uric acid, the protein content of the crude enzyme of Lactobacillus casei YWC-01 strain is 0.1-1.0 g / kg (mg / g), preferably 0.8-1.0 g / kg.
[0070] The third aspect of the present invention provides a method for preparing the Lactobacillus casei YWC-01 preparation for biodegrading uric acid as described in the second aspect of the present invention, comprising:
[0071] Step B, inoculating the fermentation bacteria into a fermentation medium, and culturing the culture at 30-40° C., preferably 38-40° C., for 3-5 days to obtain a fermentation culture of Lactobacillus casei YWC-01 strain;
[0072] Step C, centrifuging the fermentation culture of Lactobacillus casei YWC-01 strain to harvest bacterial cells of Lactobacillus casei YWC-01 strain;
[0073] The fermentation bacteria are obtained by seed culture of the corresponding Lactobacillus casei YWC-01 strain.
[0074] As those skilled in the art know, currently, 16S rRNA is commonly used internationally for molecular identification of prokaryotic microorganisms, so 16S rRNA can be used for comparison to obtain homology in similarity comparison. Therefore, the fermentation strain used in the present invention is not limited to the field isolate used in the present invention. 16S rDNA is a DNA sequence corresponding to the rRNA encoded on the bacterial chromosome, and exists in the genome of all prokaryotic microorganisms. Figure 1 The molecular evolutionary tree of Lactobacillus casei YWC-01 strain based on 16S rDNA is shown.
[0075] In the above step C, the centrifugal separation treatment includes resuspending and washing the precipitate (i.e., bacterial cells of Lactobacillus casei YWC-01 strain) obtained by centrifugal separation of the liquid fermentation culture with physiological saline, and then centrifuging to obtain bacterial cells of Lactobacillus casei YWC-01 strain.
[0076] The present invention has no particular limitation on the conditions for centrifugal separation in the above step C. In some embodiments of the present invention, for example, the substance to be separated may be centrifuged at 8000-10000 r / min for 10 min.
[0077] According to the method of the present invention, the fermentation culture is static or fermentation culture of the strain, and the fermentation strain is inoculated into the fermentation medium in the form of seed liquid. The inoculation amount of the seed liquid is 1%-10% (v / v); preferably, the inoculation amount of the seed liquid is 5%-10% (v / v); more preferably, the inoculation amount of the seed liquid is 10% (v / v).
[0078] Specifically, the fermentation medium comprises the following components in 1L of water:
[0079]
[0080] Preferably, the fermentation medium comprises the following components in 1L of water:
[0081]
[0082] In some embodiments of the present invention, the initial pH of the fermentation medium is adjusted to 7-8 using 40% (wt / v) sodium hydroxide solution and 36% (v / v) hydrochloric acid solution.
[0083] According to some embodiments of the present invention, the preparation method of the Lactobacillus casei YWC-01 preparation involved in the present invention also includes a seed culture step A before step B: picking the monoclonal colony of the Lactobacillus casei YWC-01 strain provided by the present invention and inoculating it into 100 mL of fermentation liquid culture medium, and culturing it at a temperature of 38°C for 3 days to obtain a fermentation strain (seed liquid).
[0084] The inventors studied the effects of different temperatures on the growth of Lactobacillus casei YWC-01 and found that Lactobacillus casei YWC-01 grew faster at a temperature of 38°C.
[0085] According to some embodiments of the present invention, the preparation method further comprises:
[0086] Step K, subjecting the cell suspension of the Lactobacillus casei YWC-01 strain to cell disruption in an ice-water bath (i.e., an ice-water mixture, 0-4° C.) to obtain a cell-free disrupted solution of the Lactobacillus casei YWC-01 strain;
[0087] Step L, centrifuging the cell-free disrupted liquid of Lactobacillus casei YWC-01 strain, and taking the supernatant cell-free extract as the crude enzyme of Lactobacillus casei YWC-01 strain.
[0088] The present invention has no particular limitation on the conditions for centrifugal separation in the above step L. In some embodiments of the present invention, for example, the separation material may be centrifuged at 15000-18000 r / min for 10-20 min.
[0089] The fourth aspect of the present invention provides a use of the Lactobacillus casei YWC-01 preparation for biodegrading uric acid according to the second aspect of the present invention or the Lactobacillus casei YWC-01 preparation for biodegrading uric acid prepared by the preparation method according to the third aspect of the present invention in the preparation of a uric acid-lowering agent, which comprises:
[0090] Step D, washing the bacterial cells of Lactobacillus casei YWC-01 strain with physiological saline to obtain a pure bacterial cell product of Lactobacillus casei YWC-01 strain;
[0091] Step E, in a physiological saline system, under low temperature conditions of 0°C-4°C, using ultrasonic waves to disrupt the pure bacterial cells of Lactobacillus casei YWC-01 strain, and taking the supernatant after centrifugation to obtain a cell-free extract as a crude enzyme pure product of Lactobacillus casei YWC-01 strain;
[0092] Step F, freeze-drying the pure bacterial cell product and / or the pure crude enzyme product of Lactobacillus casei YWC-01 strain, and diluting the freeze-dried Lactobacillus casei YWC-01 preparation to prepare a uric acid-lowering agent.
[0093] In some embodiments of the present invention, in step F, the freeze-dried Lactobacillus casei YWC-01 preparation is diluted with physiological saline to prepare a liquid uric acid-lowering agent.
[0094] In other embodiments of the present invention, in step F, the freeze-dried Lactobacillus casei YWC-01 preparation is diluted with edible starch to prepare a solid uric acid-lowering agent.
[0095] In some preferred embodiments of the present invention, the uric acid lowering agent is an oral preparation.
[0096] III. Related materials and detection methods in the present invention
[0097] 1. Materials
[0098] The enzyme involved in the present invention adopts apple as raw material and is prepared by natural bacteria fermentation.
[0099] 2. Detection method
[0100] (1) The cell concentration in the present invention is determined by the following method:
[0101] The cell concentration of Lactobacillus casei YWC-01 was determined by diluting the culture of Lactobacillus casei YWC-01 by a certain multiple with physiological saline, and then directly measuring the cell concentration therein using a flow cytometer (SYSMEX, Germany).
[0102] (2) The uric acid concentration in the present invention is determined by the following method:
[0103] The uric acid concentration was determined by high performance liquid chromatography (Shimadzu LC-20AT), specifically, the chromatographic column was Kromasil C18 (4.6×250 mm, 5 μ particle size); the mobile phase was methanol: 0.5% acetic acid aqueous solution (10:90); the detection wavelength was 283 nm; the flow rate was 1 mL / min; the injection volume was 20 μL; and the temperature was 35°C.
[0104] (3) The crude enzyme protein concentration in the present invention is measured by the following method:
[0105] The cell-free extract of Lactobacillus casei YWC-01 was diluted a certain number of times with phosphate buffer solution, and Coomassie Brilliant Blue G-250 dye reagent was added in proportion to react for 10 minutes. The absorbance was measured at 595 nm using a 722S visible spectrophotometer (Shanghai Lingguang), and the protein concentration was calculated using the standard curve method.
[0106] III. Examples
[0107] The present invention is described in detail below through specific examples. The experimental methods described below, unless otherwise specified, are all routine laboratory methods. The experimental materials described below, unless otherwise specified, can all be obtained from commercial channels.
[0108] Embodiment 1:
[0109] (1) Prepare a growth medium for Lactobacillus casei YWC-01, the composition of which is (per liter): 10 g of peptone, 10 g of beef extract, 10 g of yeast powder, and 10 g of glucose, and adjust the initial pH to 7.5. Add 100 ml of the prepared liquid medium into a 500 ml Erlenmeyer flask, sterilize at high temperature and high pressure (115°C) for 30 minutes, and then sterilize under ultraviolet irradiation in a clean bench for another 20 minutes.
[0110] (2) Under aseptic conditions in a clean bench, 10 ml of Lactobacillus casei YWC-01 bacterial solution was inoculated into a triangular flask liquid culture medium, and after static culture at 38° C. for 3 days, Lactobacillus casei YWC-01 cells were harvested by centrifugation (8000 rpm, 10 minutes) and discarding the supernatant.
[0111] Get Lactobacillus casei YWC-01 cell suspension 20mL and join in the 50mL glass tube and insert in ice water, with ultrasonic cell disruptor, Lactobacillus casei YWC-01 cell is broken, condition is: ultrasonic power 400W, interval 2 seconds, ultrasonic oscillation 10 seconds, break time 15 minutes (each 5 minutes).After cell disruption finishes, cell disruption liquid is carried out centrifugal at 15000 rev / mins for 20 minutes, slowly pour out supernatant as the cell-free extract (crude enzyme) of Lactobacillus casei YWC-01 then.
[0112] (3) According to different uric acid concentrations, the cultured Lactobacillus casei YWC-01 cells and crude enzymes were added in a certain proportion as a fast, safe and efficient biocatalyst to achieve the purpose of rapid and efficient degradation and removal of uric acid.
[0113] Figure 1 It showed that the strain we screened was most closely related to Lactobacillus casei, so it was named Lactobacillus casei YWC-01 strain.
[0114] Figure 2 It showed that when the initial cell concentration of Lactobacillus casei YWC-01 was 8×10 8 / mL, the initial concentration of uric acid of 1 g / L can be completely degraded within 48 hours, indicating that Lactobacillus casei YWC-01 has a strong biodegradation ability for uric acid.
[0115] Figure 3The results showed that the cell-free extract (crude enzyme) of Lactobacillus casei YWC-01 could catalyze the degradation of uric acid at a faster rate. At a protein concentration of 0.8 g / L, the initial uric acid concentration of 1 g / L could be completely degraded within 18 hours, indicating a higher uric acid degradation rate.
[0116] It should be noted that the embodiments described above are only preferred embodiments of the present invention, which are used to explain the present invention and do not constitute any limitation to the present invention. The present invention has been described with reference to typical embodiments, but it should be understood that the words used therein are descriptive and explanatory words, rather than restrictive words. The present invention may be modified as specified within the scope of the claims of the present invention, and the present invention may be revised without departing from the scope and spirit of the present invention. Although the present invention described therein relates to specific methods, materials and embodiments, it does not mean that the present invention is limited to the specific examples disclosed therein. On the contrary, the present invention can be extended to all other methods and applications with the same functions.
Claims
1. A Lactobacillus casei YWC-01 strain for degrading uric acid, which can produce an enzyme that catalyzes the degradation of uric acid and has a deposit number of CGMCC No.31534.
2. Lactobacillus casei YWC-01 strain according to claim 1, characterized in that, The initial bacterial cell concentration of Lactobacillus casei YWC-01 strain was 8×10 8 / mL, the initial concentration of uric acid of 1g / L can be completely degraded and removed within 48 hours.
3. Lactobacillus casei YWC-01 strain according to claim 1, characterized in that, The crude enzyme produced by the Lactobacillus casei YWC-01 strain can completely remove uric acid with an initial concentration of 1 g / L within 18 hours at a protein concentration of 0.8 g / L.
4. A Lactobacillus casei YWC-01 preparation for degrading uric acid, comprising bacterial cells and / or crude enzyme of the Lactobacillus casei YWC-01 strain as described in any one of claims 1-3; preferably, the Lactobacillus casei YWC-01 preparation comprises the Lactobacillus casei YWC-01 strain as described in any one of claims 1-3.
5. Lactobacillus casei YWC-01 preparation according to claim 4, characterized in that, The uric acid-degrading Lactobacillus casei YWC-01 preparation is a liquid preparation; preferably, in the uric acid-degrading liquid preparation, the bacterial cell concentration of Lactobacillus casei YWC-01 strain is (1-10)×10 8 / mL; and / or, in the liquid preparation for degrading uric acid, the protein concentration of the crude enzyme of Lactobacillus casei YWC-01 strain is 0.1-1.0 g / L; Alternatively, the uric acid-degrading Lactobacillus casei YWC-01 preparation is a solid powder preparation; preferably, in the uric acid-degrading solid powder preparation, the content of bacterial cells of Lactobacillus casei YWC-01 strain is (1-10)×10 8 / g, more preferably (8-10)×10 8 / g; and / or, in the solid powder preparation for degrading uric acid, the protein content of the crude enzyme of Lactobacillus casei YWC-01 strain is 0.1-1.0 g / kg, more preferably 0.8-1.0 g / kg.
6. A method for preparing a Lactobacillus casei YWC-01 preparation for degrading uric acid as claimed in any one of claims 4 or 5, comprising: Step B, inoculating the fermentation bacteria into a fermentation medium for fermentation culture to obtain a fermentation culture of Lactobacillus casei YWC-01 strain; Step C, centrifuging the fermentation culture of Lactobacillus casei YWC-01 strain to harvest bacterial cells of Lactobacillus casei YWC-01 strain; The fermentation bacteria are obtained by seed culture of the corresponding Lactobacillus casei YWC-01 strain.
7. The preparation method according to claim 6, characterized in that: The fermentation medium, based on 1L of water, includes the following components in 1L of water: Preferably, the pH value of the fermentation medium is 7-8; Further preferably, in step B, the fermentation culture temperature is 30-40°C, preferably 38-40°C.
8. The preparation method according to claim 6 or 7, characterized in that: The preparation method further comprises: Step K, subjecting the cell suspension of Lactobacillus casei YWC-01 strain to cell disruption treatment under low temperature conditions to obtain a cell-free disruption solution of Lactobacillus casei YWC-01 strain; Step L, centrifuging the cell-free disrupted liquid of Lactobacillus casei YWC-01 strain, and taking the supernatant cell-free extract as the crude enzyme of Lactobacillus casei YWC-01 strain; Wherein, the low temperature is 0-4°C.
9. Use of the uric acid-degrading Lactobacillus casei YWC-01 preparation as claimed in claim 4 or 5 or the uric acid-degrading Lactobacillus casei YWC-01 preparation obtained by the preparation method as claimed in any one of claims 6 to 8 in the preparation of a uric acid-lowering agent, comprising: Step D, washing the bacterial cells of Lactobacillus casei YWC-01 strain with physiological saline to obtain a pure bacterial cell product of Lactobacillus casei YWC-01 strain; Step E, in a physiological saline system, under low temperature conditions, using ultrasound to disrupt the pure bacterial cells of Lactobacillus casei YWC-01 strain, and taking the supernatant after centrifugation to obtain a cell-free extract as a crude enzyme pure product of Lactobacillus casei YWC-01 strain; Step F, freeze-drying the pure bacterial cell product and / or the pure crude enzyme product of Lactobacillus casei YWC-01 strain, and diluting the freeze-dried Lactobacillus casei YWC-01 preparation to prepare a uric acid degrading agent; Wherein, the low temperature is 0-4°C.
10. The use according to claim 9, characterized in that: In step F, the freeze-dried Lactobacillus casei YWC-01 preparation is diluted with physiological saline to prepare a liquid uric acid-lowering agent; Alternatively, in step F, the freeze-dried Lactobacillus casei YWC-01 preparation is diluted with edible starch to prepare a solid uric acid-lowering agent; Preferably, the uric acid lowering agent is an oral preparation.
Citation Information
Patent Citations
Lactobacillus casei strain and probiotic composition for lowering blood uric acid and application thereof
CN108486007A
Lactobacillus paracasei A21151 with effects of reducing blood uric acid and resisting inflammation and application of lactobacillus paracasei A21151
CN117025456A
Lactobacillus paracasei YYS-UR capable of reducing uric acid and blood sugar and application of lactobacillus paracasei YYS-UR
CN117625474A
Lactobacillus casei M2a, bacterial liquid, composition and application of lactobacillus casei M2a
CN118652780A
Probiotic strain for reducing serum uric acid, composition and use thereof
US20240024385A1
